- Home
- SLP vs PROK Comparison
SLP vs PROK Comparison
Compare SLP & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLP | PROK |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 371.9M | 316.0M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SLP | PROK |
|---|---|---|
| Price | $18.42 | $1.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $24.00 | $7.40 |
| AVG Volume (30 Days) | 154.1K | ★ 1.1M |
| Earning Date | 04-09-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $59,577,000.00 | $893,000.00 |
| Revenue This Year | $3.80 | N/A |
| Revenue Next Year | $5.90 | N/A |
| P/E Ratio | $42.84 | ★ N/A |
| Revenue Growth | 10.52 | ★ 1075.00 |
| 52 Week Low | $11.09 | $1.30 |
| 52 Week High | $21.01 | $3.48 |
Technical Indicators
Market Signals| Indicator | SLP | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 60.85 | 54.22 |
| Support Level | $18.22 | $1.73 |
| Resistance Level | $18.46 | $2.17 |
| Average True Range (ATR) | 0.02 | 0.11 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 50.00 | 42.11 |
Price Performance
Historical ComparisonAbout SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.